Trial Profile
A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Novartis Pharma
- 05 Oct 2021 Status changed from recruiting to completed.
- 02 Apr 2012 New trial record